Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Recurrent ANCA-associated small vessel vasculitis after transplantation : A pooled analysis

Nachman, Patrick H. ; Segelmark, Marten LU ; Westman, Kerstin LU ; Hogan, Susan L. ; Satterly, Karen K. ; Jennette, J. Charles and Falk, Ronald (1999) In Kidney International 56(4). p.1544-1550
Abstract

Background. Recurrent antineutrophil cytoplasmic antibody (ANCA)- associated small vessel vasculitis (ANCA-SVV) after renal transplantation has been described in case series. However, general information regarding the frequency, character, and predictors of recurrent disease after transplantation is currently lacking. We considered the rate of relapse, whether a positive ANCA at the time of transplantation predicted relapse, and whether cyclosporine A prevented recurrent disease. Methods. We performed a pooled analysis of published data, added to the experience at the Universities of North Carolina (14 patients) and Lund, Sweden (11 patients). To avoid reporting bias, only case series were included for analysis. Subgroup analysis was... (More)

Background. Recurrent antineutrophil cytoplasmic antibody (ANCA)- associated small vessel vasculitis (ANCA-SVV) after renal transplantation has been described in case series. However, general information regarding the frequency, character, and predictors of recurrent disease after transplantation is currently lacking. We considered the rate of relapse, whether a positive ANCA at the time of transplantation predicted relapse, and whether cyclosporine A prevented recurrent disease. Methods. We performed a pooled analysis of published data, added to the experience at the Universities of North Carolina (14 patients) and Lund, Sweden (11 patients). To avoid reporting bias, only case series were included for analysis. Subgroup analysis was performed by disease category (Wegener's granulomatosis, microscopic polyangiitis, or necrotizing crescentic glomerulonephritis) and ANCA staining pattern. Results. ANCA-SVV recurred in 17.3% of all patients (N = 127), in 20% of cyclosporine A-treated patients (N = 85), and in 25.6% of patients with circulating ANCA at the time of transplantation (N = 39). There was no statistically significant difference in the relapse rate between patients treated and those not treated with cyclosporine A (P = 0.45), between those with and without circulating ANCA at the time of transplant (P = 0.75), or between patients with Wegener's granulomatosis and those with microscopic polyangiitis or necrotizing crescentic glomerulonephritis alone (P = 0.62). Conclusion. There is a substantial relapse rate in the ANCA-SVV population. Therapy with cyclosporine A does not protect against recurrent ANCA-SVV, and the presence of a positive ANCA at the time of transplantation does not preclude transplantation. These conclusions must be substantiated with a prospective study of renal transplantation in patients with ANCA-SVV so as to optimize their management.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
ANCA, Cyclosporine A, End-stage renal failure, Relapse, Renal transplantation
in
Kidney International
volume
56
issue
4
pages
1544 - 1550
publisher
Nature Publishing Group
external identifiers
  • pmid:10504506
  • scopus:0032821020
ISSN
0085-2538
DOI
10.1046/j.1523-1755.1999.00666.x
language
English
LU publication?
yes
id
cacf5d46-f3fa-484f-b9ce-2d862c93f2b6
date added to LUP
2020-05-20 16:55:30
date last changed
2024-05-01 11:27:26
@article{cacf5d46-f3fa-484f-b9ce-2d862c93f2b6,
  abstract     = {{<p>Background. Recurrent antineutrophil cytoplasmic antibody (ANCA)- associated small vessel vasculitis (ANCA-SVV) after renal transplantation has been described in case series. However, general information regarding the frequency, character, and predictors of recurrent disease after transplantation is currently lacking. We considered the rate of relapse, whether a positive ANCA at the time of transplantation predicted relapse, and whether cyclosporine A prevented recurrent disease. Methods. We performed a pooled analysis of published data, added to the experience at the Universities of North Carolina (14 patients) and Lund, Sweden (11 patients). To avoid reporting bias, only case series were included for analysis. Subgroup analysis was performed by disease category (Wegener's granulomatosis, microscopic polyangiitis, or necrotizing crescentic glomerulonephritis) and ANCA staining pattern. Results. ANCA-SVV recurred in 17.3% of all patients (N = 127), in 20% of cyclosporine A-treated patients (N = 85), and in 25.6% of patients with circulating ANCA at the time of transplantation (N = 39). There was no statistically significant difference in the relapse rate between patients treated and those not treated with cyclosporine A (P = 0.45), between those with and without circulating ANCA at the time of transplant (P = 0.75), or between patients with Wegener's granulomatosis and those with microscopic polyangiitis or necrotizing crescentic glomerulonephritis alone (P = 0.62). Conclusion. There is a substantial relapse rate in the ANCA-SVV population. Therapy with cyclosporine A does not protect against recurrent ANCA-SVV, and the presence of a positive ANCA at the time of transplantation does not preclude transplantation. These conclusions must be substantiated with a prospective study of renal transplantation in patients with ANCA-SVV so as to optimize their management.</p>}},
  author       = {{Nachman, Patrick H. and Segelmark, Marten and Westman, Kerstin and Hogan, Susan L. and Satterly, Karen K. and Jennette, J. Charles and Falk, Ronald}},
  issn         = {{0085-2538}},
  keywords     = {{ANCA; Cyclosporine A; End-stage renal failure; Relapse; Renal transplantation}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{1544--1550}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Kidney International}},
  title        = {{Recurrent ANCA-associated small vessel vasculitis after transplantation : A pooled analysis}},
  url          = {{http://dx.doi.org/10.1046/j.1523-1755.1999.00666.x}},
  doi          = {{10.1046/j.1523-1755.1999.00666.x}},
  volume       = {{56}},
  year         = {{1999}},
}